OhmBody

OhmBody operates at the intersection of femtech, consumer wellness, wearable medical devices, and neurostimulation. Its stated differentiation is a drug-free and hormone-free approach to menstrual support, delivered through a reusable wearable device with adhesive earpieces. The product is positioned for recurring cycle-related use while also addressing adjacent wellness outcomes such as sleep, mood, focus, energy, and digestion. The company also emphasizes neuroscience, clinical research, and medical-grade neuromodulation adapted for wellness use, which distinguishes it from general-purpose fitness wearables and supplement-based menstrual products. Its HSA/FSA eligibility and 60-day money-back guarantee reduce some consumer adoption friction, while Classic and Active earpiece options target both everyday use and higher-movement activities. OVO’s December 2025 distribution expansion provides evidence of ecosystem integration. OhmBody’s clearest market identity is an early-stage, specialized menstrual-wellness application of auricular neurostimulation.

OhmBody appears to be in an early commercialization phase. The company was founded in 2025 and is associated with an employee range of 11 to 50, indicating a small operating base relative to established medical-device and consumer-health companies. Its reported Series A funding of $15 million provides meaningful capital for a young hardware business, but the round date, investor list, valuation, and subsequent financing history are not publicly available in the current profile. A notable commercial inflection point came on Dec 17, 2025, when OVO began offering the OhmBody device through its online store. This was followed by a CES 2026 showcase announced on Jan 2, 2026, suggesting a deliberate effort to build awareness through retail distribution and industry events. The April 2026 Edison Award recognition added third-party validation in women’s health and reproductive innovation. The product portfolio currently centers on the OhmBody Starter Kit rather than a broad family of disclosed devices. Website capabilities such as online purchasing and multiple payment options support direct-to-consumer sales, while OVO adds an external channel. However, there is no disclosed hiring momentum, revenue data, repeat-purchase rate, clinical adoption metric, or additional product pipeline. The trajectory is therefore promising but not yet quantifiably proven beyond early distribution and recognition milestones.